Related Experiment Video

Updated: Aug 13, 2026

Toxoplasma gondii Cyst Wall Formation in Activated Bone Marrow-derived Macrophages and Bradyzoite Conditions
09:56

Toxoplasma gondii Cyst Wall Formation in Activated Bone Marrow-derived Macrophages and Bradyzoite Conditions

Published on: August 12, 2010

Anti-Toxoplasma gondii antibodies in patients with chronic heart failure

Süleyman Yazar, Mustafa Gur, Ibrahim Ozdogru

    Journal of Medical Microbiology
    |January 3, 2006
    PubMed

    Insights

    Patients with chronic heart failure (CHF) show a higher rate of Toxoplasma infection. Periodic screening for toxoplasmosis in CHF patients is recommended to prevent its spread.

    Area of Science:

    • Cardiology
    • Infectious Diseases
    • Immunology

    Background:

    • Chronic heart failure (CHF) involves complex interactions between cardiovascular, neuroendocrine, and immune systems.
    • Toxoplasma gondii infection is a widespread parasitic disease with potential implications for various health conditions.

    Purpose of the Study:

    • To investigate the seropositivity rate of anti-Toxoplasma IgG and IgM antibodies in patients diagnosed with chronic heart failure.
    • To compare the seropositivity rates between CHF patients and healthy individuals.

    Main Methods:

    • Enzyme-Linked Immunosorbent Assay (ELISA) was employed to detect anti-Toxoplasma IgG and IgM antibodies.
    • A cohort of 97 patients with CHF and 50 healthy volunteers participated in the study.

    Main Results:

    • The seropositivity rate for anti-Toxoplasma IgG antibodies was significantly higher in CHF patients (68%) compared to healthy volunteers (36%).
    • No significant difference was observed for IgM antibodies, suggesting a chronic rather than acute infection.

    Conclusions:

    • Chronic heart failure patients exhibit a higher prevalence of Toxoplasma infection.
    • Regular parasitological screening for toxoplasmosis is advisable in CHF patients to mitigate potential dissemination and complications.

    More Related Videos

    3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii06:33

    3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii

    Published on: December 9, 2014

    Related Concept Videos

    Toxoplasmosis01:28

    Toxoplasmosis

    Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    American Trypanosomiasis01:22

    American Trypanosomiasis

    Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
    Myasthenia Gravis: Diagnostic Tests01:15

    Myasthenia Gravis: Diagnostic Tests

    Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
    The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...